Sep 13, 2023 / 03:30PM GMT
Unidentified Analyst -
Amazing. It's amazing. Thank you. Welcome, everybody. Obviously, I'm Patrick, I've run the U.S. medtech team here at Morgan Stanley. I'm delighted to have obviously Liam and Larry here, CEO and Head of IR and Strategy to chat about all things Teleflex.
The -- before we get started, I have some fun disclosures, morganstanley.com/researchdisclosures or chat to your sales rep. I managed to go that bit down pretty fast now. So that's pretty good. Thank you so much for agreeing to do this and coming along. And yes, it's been great.
Questions and Answers:
Unidentified Analyst -Maybe the best way to do kind of -- you guys have quite a broad view of the health care system overall. And so far, first half of this year has been a lot of procedure volumes. It's been -- volume has been generally pretty strong. How are you thinking about the next 6, 12, 18 months in terms of volumes?
Liam J. Kelly - Teleflex Incorporated - Chairman, President & CEO
So I think that as we look at the environment that we're
Trustpilot
